16 assets in Friedreich Ataxia

Therapeutic assets addressing Friedreich Ataxia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Omaveloxolone Friedreich Ataxia	Biogen	P3	BB (70)
Vatiquinone Friedreich Ataxia	PTC Therapeutics	P3	BB (66)
L-Methionyl-L-Tyrosylglycyl-L-Arginyl-L-Lysyl-L-Lysyl-L-Arginyl-L-Arginyl-L-Glutaminyl-L-Arginyl-L-Arginyl-L-Arginylglycylglycine Fusion Protein With Frataxin (Human Isoform 1 Precursor) Friedreich Ataxia	Larimar Therapeutics, Inc.	P2	BB (64)
dt-216p2 Friedreich Ataxia	Design Therapeutics, Inc.	P1/2	CCC (54)
Multiple Vitamins Injection Friedreich Ataxia	RWTH Aachen University	P2	CCC (53)
Artesunate Friedreich Ataxia	Institut National de la Santé Et de la Recherche Médicale, France	P1/2	CCC (50)
dt-216 Friedreich Ataxia	Design Therapeutics, Inc.	P1	CCC (50)
Elamipretide Trihydrochloride Friedreich Ataxia	Children's Hospital of Philadelphia	P1/2	CCC (50)
High Dose Lx2006 Friedreich Ataxia	Lexeo Therapeutics	P1/2	CC (47)
Low Dose Lx2006 Friedreich Ataxia	Lexeo Therapeutics	P1/2	CC (47)
Aavrh.10Hfxn, Serotype Rh.10 Adeno-Associated Virus Gene Transfer Vector Expressing The Cdna Coding For Human Fxn Friedreich Ataxia	Weill Medical College of Cornell University	P1	CC (43)
asp2016 Friedreich Ataxia	Astellas Gene Therapies	P1	CC (43)
Nomlabofusp Friedreich Ataxia	Larimar Therapeutics, Inc.	P1	CC (43)
Prednisolone Friedreich Ataxia	Astellas Gene Therapies	P1	CC (43)
Prednisone Friedreich Ataxia	Weill Medical College of Cornell University	P1	CC (43)
Sgt-212 Friedreich Ataxia	Solid Biosciences Inc.	P1	CC (43)